Inhibition of the CyclinD1 promoter in response to sonic hedgehog signaling pathway transduction is mediated by Gli1

Lin,Zhongxiao; Sheng,Hansong; You,Chaoguo; Cai,Ming; Zhang,Yiping; Yu,Li  Sheng; Yu,Xiaoming; Lin,Jian; Zhang,Nu

doi:10.3892/etm.2016.3969

Inhibition of the CyclinD1 promoter in response to sonic hedgehog signaling pathway transduction is mediated by Gli1

Authors:
- Zhongxiao Lin
- Hansong Sheng
- Chaoguo You
- Ming Cai
- Yiping Zhang
- Li Sheng Yu
- Xiaoming Yu
- Jian Lin
- Nu Zhang
View Affiliations

Affiliations: Department of Neurosurgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: December 13, 2016 https://doi.org/10.3892/etm.2016.3969
Pages: 307-314
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Medulloblastoma (MB) is the most common malignant tumor of the central nervous system in children. Accumulating evidence suggests a major role for the activation of the sonic hedgehog (SHH) signaling pathway in the development of MB cells; however, the mechanisms underlying the effect of this pathway on tumor survival and growth remain poorly understood. The Gli family zinc finger 1 (Gli1) transcription factor is considered as a mediator of the SHH signaling pathway in MB cells. Therefore, the present study investigated whether the SHH signaling pathway promotes the apoptosis of MB cells via downregulation of Gli1. GANT61, a novel Gli1 inhibitor, is known to have an in vitro activity against tumors. In the current study, Daoy cells were treated with different concentrations of GANT61 for 24 h, and the effect on cell proliferation was assayed by cell counting kit‑8 assay. In addition, the cell cycle progression and apoptosis were assayed by flow cytometry analysis and hematoxylin-eosin (HE) staining. The effects of GANT61 treatment on SHH signaling pathway at the mRNA level were assayed by polymerase chain reaction (PCR). To further elucidate the inhibitory effects of GANT61 on the expression of Gli1 and CyclinD1, their protein levels were examined by western blot and immunofluorescence. The results indicated that GANT61 significantly inhibited the proliferation of Daoy cells in a dose‑dependent manner, compared with the control group (P<0.05). HE staining revealed that cells had increasingly abnormal protuberance with increasing GANT61 concentration. Flow cytometry analysis also demonstrated that GANT61 induced G1/S arrest and apoptosis of Daoy cells in a dose‑dependent manner (P<0.05). Gli1 and CyclinD1 mRNA expression levels were downregulated by GANT61 treatment (P<0.05); similarly, their protein levels were downregulated by GANT61 treatment in a dose‑dependent manner (P<0.05). In conclusion, Gli1 expression was significantly associated with CyclinD1 expression in MB. These data demonstrated that Gli1 is an important mediator of the SHH pathway activity in MB, and may be a novel agent for use in combined chemotherapeutic regimens.

View Figures

View References

1	Gerber NU, Mynarek M, von Hoff K, Friedrich C, Resch A and Rutkowski S: Recent developments and current concepts in medulloblastoma. Cancer Treat Rev. 40:356–365. 2014. View Article : Google Scholar : PubMed/NCBI
2	Gilbertson RJ: Medulloblastoma: Signalling a change in treatment. Lancet Oncol. 5:209–218. 2004. View Article : Google Scholar : PubMed/NCBI
3	Packer RJ and Vezina G: Management of and prognosis with medulloblastoma: Therapy at a crossroads. Arch Neurol. 65:1419–1424. 2008. View Article : Google Scholar : PubMed/NCBI
4	Rutkowski S, von Hoff K, Emser A, Zwiener I, Pietsch T, Figarella-Branger D, Giangaspero F, Ellison DW, Garre ML, Biassoni V, et al: Survival and prognostic factors of early childhood medulloblastoma: An international meta-analysis. J Clin Oncol. 28:4961–4968. 2010. View Article : Google Scholar : PubMed/NCBI
5	Moxon-Emre I, Bouffet E, Taylor MD, Laperriere N, Scantlebury N, Law N, Spiegler BJ, Malkin D, Janzen L and Mabbott D: Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol. 32:1760–1768. 2014. View Article : Google Scholar : PubMed/NCBI
6	Archer TC, Weeraratne SD and Pomeroy SL: Hedgehog-GLI pathway in medulloblastoma. J Clin Oncol. 30:2154–2156. 2012. View Article : Google Scholar : PubMed/NCBI
7	Gotschel F, Berg D, Gruber W, Bender C, Eberl M, Friedel M, Sonntag J, Rüngeler E, Hache H, Wierling C, et al: Synergism between Hedgehog-GLI and EGFR signaling in Hedgehog-responsive human medulloblastoma cells induces downregulation of canonical Hedgehog-target genes and stabilized expression of GLI1. PLoS One. 8:e654032013. View Article : Google Scholar : PubMed/NCBI
8	Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, et al: Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 29:1424–1430. 2011. View Article : Google Scholar : PubMed/NCBI
9	Mcmillan R and Matsui W: Molecular pathways: The hedgehog signaling pathway in cancer. Clin Cancer Res. 18:4883–4888. 2012. View Article : Google Scholar : PubMed/NCBI
10	Shahi MH, Afzal M, Sinha S, Eberhart CG, Rey JA, Fan X and Castresana JS: Regulation of sonic hedgehog-GLI1 downstream target genes PTCH1, Cyclin D2, Plakoglobin, PAX6 and NKX2.2 and their epigenetic status in medulloblastoma and astrocytoma. BMC Cancer. 10:6142010. View Article : Google Scholar : PubMed/NCBI
11	Kenney AM, Cole MD and Rowitch DH: Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development. 130:15–28. 2003. View Article : Google Scholar : PubMed/NCBI
12	Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
13	Barbash O, Zamfirova P, Lin DI, Chen X, Yang K, Nakagawa H, Lu F, Rustgi AK and Diehl JA: Mutations in Fbx4 inhibit dimerization of the SCF (Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell. 14:68–78. 2008. View Article : Google Scholar : PubMed/NCBI
14	Fu M, Wang C, Li Z, Sakamaki T and Pestell RG: Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
15	Musgrove EA: Cyclins: Roles in mitogenic signaling and oncogenic transformation. Growth Factors. 24:13–19. 2006. View Article : Google Scholar : PubMed/NCBI
16	Fu J, Rodova M, Roy SK, Sharma J, Singh KP, Srivastava RK and Shankar S: GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 330:22–32. 2013. View Article : Google Scholar : PubMed/NCBI
17	Peukert S and Miller-Moslin K: Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. ChemMedChem. 5:500–512. 2010. View Article : Google Scholar : PubMed/NCBI
18	Mazumdar T, Devecchio J, Shi T, Jones J, Agyeman A and Houghton JA: Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res. 71:1092–1102. 2011. View Article : Google Scholar : PubMed/NCBI
19	Lin Z, Li S, Sheng H, Cai M, Ma LY, Hu L, Xu S, Yu LS and Zhang N: Suppression of GLI sensitizes medulloblastoma cells to mitochondria-mediated apoptosis. J Cancer Res Clin Oncol. 142:2469–2478. 2016. View Article : Google Scholar : PubMed/NCBI
20	Rafiee M, Keramati MR, Ayatollahi H, Sadeghian MH, Barzegar M, Asgharzadeh A and Alinejad M: Down-Regulation of Ribosomal S6 kinase RPS6KA6 in Acute Myeloid Leukemia Patients. Cell J. 18:159–164. 2016.PubMed/NCBI
21	Floris I, Billard H, Boquien CY, Joram-Gauvard E, Simon L, Legrand A, Boscher C, Rozé JC, Bolaños-Jiménez F and Kaeffer B: MiRNA Analysis by Quantitative PCR in Preterm Human Breast Milk Reveals Daily Fluctuations of hsa-miR-16-5p. PLoS One. 10:e1404882015. View Article : Google Scholar
22	Huang XB, Shi Y, Wang CS, Wang XD, Cheng J and Che FF: Synergistic Inhibitory Effect of Arsenic Trioxide Combined with Itraconazole on Hedgehog Pathway of Multiple Myeloma NCI-H929 Cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 24:1459–1465. 2016.(In Chinese). PubMed/NCBI
23	Du WZ, Feng Y, Wang XF, Piao XY, Cui YQ, Chen LC, Lei XH, Sun X, Liu X, Wang HB, et al: Curcumin suppresses malignant glioma cells growth and induces apoptosis by inhibition of SHH/GLI1 signaling pathway in vitro and vivo. CNS Neurosci Ther. 19:926–936. 2013. View Article : Google Scholar : PubMed/NCBI
24	Nakamura M and Katano M: Hedgehog signaling pathway and its impact on development of cancer therapy. Fukuoka Igaku Zasshi. 99:102–106. 2008.(In Japanese). PubMed/NCBI
25	Malek R, Matta J, Taylor N, Perry ME and Mendrysa SM: The p53 inhibitor MDM2 facilitates Sonic Hedgehog-mediated tumorigenesis and influences cerebellar foliation. PLoS One. 6:e178842011. View Article : Google Scholar : PubMed/NCBI
26	Sahebjam S, Siu LL and Razak AA: The utility of hedgehog signaling pathway inhibition for cancer. Oncologist. 17:1090–1099. 2012. View Article : Google Scholar : PubMed/NCBI
27	Wang X, Venugopal C, Manoranjan B, McFarlane N, O'Farrell E, Nolte S, Gunnarsson T, Hollenberg R, Kwiecien J, Northcott P, et al: Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene. 31:187–199. 2012. View Article : Google Scholar : PubMed/NCBI
28	Jiang J and Hui CC: Hedgehog signaling in development and cancer. Dev Cell. 15:801–812. 2008. View Article : Google Scholar : PubMed/NCBI
29	Ruiz i Altaba A, Palma V and Dahmane N: Hedgehog-Gli signalling and the growth of the brain. Nat Rev Neurosci. 3:24–33. 2002. View Article : Google Scholar : PubMed/NCBI
30	Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N, et al: Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 20:732–740. 2014. View Article : Google Scholar : PubMed/NCBI
31	Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, et al: Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 19:2766–2774. 2013. View Article : Google Scholar : PubMed/NCBI
32	Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, et al: A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res. 19:258–267. 2013. View Article : Google Scholar : PubMed/NCBI
33	Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, et al: Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 20:5937–5945. 2014. View Article : Google Scholar : PubMed/NCBI
34	D'Amato C, Rosa R, Marciano R, D'Amato V, Formisano L, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fulciniti F, et al: Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 111:1168–1179. 2014. View Article : Google Scholar : PubMed/NCBI
35	Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, et al: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 361:1173–1178. 2009. View Article : Google Scholar : PubMed/NCBI
36	Kimura H, Ng JM and Curran T: Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell. 13:249–260. 2008. View Article : Google Scholar : PubMed/NCBI
37	Meani RE, Lim SW, Chang AL and Kelly JW: Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449). Australas J Dermatol. 55:218–221. 2014. View Article : Google Scholar : PubMed/NCBI
38	Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, et al: Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 25:393–405. 2014. View Article : Google Scholar : PubMed/NCBI
39	Samkari A, White J and Packer R: SHH inhibitors for the treatment of medulloblastoma. Expert Rev Neurother. 15:763–770. 2015. View Article : Google Scholar : PubMed/NCBI
40	Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D, Han D, Liu J, Englund NP, Wang Y, et al: Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett. 1:130–134. 2010. View Article : Google Scholar : PubMed/NCBI
41	Ruiz i Altaba A, Mas C and Stecca B: The Gli code: An information nexus regulating cell fate, stemness and cancer. Trends Cell Biol. 17:438–447. 2007. View Article : Google Scholar : PubMed/NCBI
42	Katoh Y and Katoh M: Hedgehog target genes: Mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med. 9:873–886. 2009. View Article : Google Scholar : PubMed/NCBI
43	Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM and Beachy PA: Medulloblastoma growth inhibition by hedgehog pathway blockade. Science. 297:1559–1561. 2002. View Article : Google Scholar : PubMed/NCBI
44	Miyazaki Y, Matsubara S, Ding Q, Tsukasa K, Yoshimitsu M, Kosai K and Takao S: Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition. Mol Cancer. 15:492016. View Article : Google Scholar : PubMed/NCBI
45	Benvenuto M, Masuelli L, De Smaele E, Fantini M, Mattera R, Cucchi D, Bonanno E, Di Stefano E, Frajese GV, Orlandi A, et al: In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget. 7:9250–9270. 2016.PubMed/NCBI
46	Li X, Hao Z, Fan R, Zou X, Jin H, Pan Y, He L, Du R, Gao L, Liu D and Fan D: CIAPIN1 inhibits gastric cancer cell proliferation and cell cycle progression by downregulating CyclinD1 and upregulating P27. Cancer Biol Ther. 6:1539–1545. 2007. View Article : Google Scholar : PubMed/NCBI
47	Seiler R, Thalmann GN, Rotzer D, Perren A and Fleischmann A: CCND1/CyclinD1 status in metastasizing bladder cancer: A prognosticator and predictor of chemotherapeutic response. Mod Pathol. 27:87–95. 2014. View Article : Google Scholar : PubMed/NCBI